ANTIPODEAN PHARMACEUTICALS BEGINS PARKINSON'S DRUG TRIAL

Antipodean Pharmaceuticals has initiated Phase II clinical trials to test the efficacy of its lead compound MitoQ (mitoquinone) in patients with Parkinson's disease in New Zealand and Australia.

The trial will involve 10 consultant neurologists at the country's main regional hospitals who will assess and advise potential participants. Parkinsons New Zealand, a non-profit patient information and support group, will also be involved to help patients.